Nonunion of Fracture Clinical Trial
Official title:
Platelet-rich Plasma Combined With Conventional Surgery in the Treatment of Atrophic Nonunion of Femoral Shaft Fractures: a Prospective, Randomized, Controlled Clinical Trial
To objectively analyze the effectiveness of platelet-rich plasma (PRP) combined with conventional surgery in the treatment of atrophic nonunion of femoral shaft fractures.
History and current related studies:
Fracture healing is a continuous process, and if any phase is disturbed by unfavorable
factors, the healing process will be blocked. Clinical studies have found that non-healing
rate of long bone fracture was approximately 5%. A certain site and type of fracture, if not
healed within a mean time (usually 3-6 months), is called delayed union by US Food and Drug
Administration. Simultaneously, the fracture that has not healed after 9 months and has no
tendency for further healing in the next 3 months is called nonunion. According to fracture
end activity, nonunion is classified into hypertrophic nonunion and atrophic nonunion.7, 8
Hypertrophic nonunion is mostly caused by unstable fixation of fracture ends, and can be
cured by strengthening the stability of fracture site using conventional surgery. Atrophic
nonunion is difficult to be cured, because of the lack of adequate blood supply and bone
formation at the fracture ends, so it is unable to form the periosteal callus. At present,
atrophic nonunion is commonly treated by internal and external fixation combined with
autologous bone graft, but this method has a long treatment cycle, and there is a situation
that cannot be cured.
Platelet-rich plasma (PRP) is blood plasma that has been enriched with platelets by
centrifuging autologous blood. Platelet after activation can secrete platelet derived growth
factor, transforming growth factor beta, vascular endothelial growth factor and epidermal
growth factor. These growth factors can promote cell proliferation and differentiation,
matrix synthesis and vascular regeneration, and accelerate tissue healing and bone repair.
PRP contains a large number of leukocytes, which can locally phagocytize bacteria, scavenge
necrotic tissue, inhibit inflammatory reaction, and resist infection. PRP fibrin can locally
build the three-dimensional structure required for tissue repair. Since Assoian et al. first
isolated PRP and used PRP in the clinic in 1984, PRP has received increasing attention in
areas such as oral and maxillofacial surgery, orthopedics, plastic surgery, and
neurosurgery.
Data management:
Clinical researchers filled in the clinical trial observation form to ensure the data were
accurate, complete and timely collected. After the trial, all data were input into the
computer. After data collection, the main clinical investigators and inspectors monitored
and checked the integrity and accuracy of the data. The data were locked by the main
investigators. Data processing statisticians further verified and checked the completeness
and accuracy of the data after data entry. Anonymized trial data will be published at
www.figshare.com.
Statistical analysis:
1. Measurement data were expressed as the mean ± SD and analyzed using SPSS 17.0 software
(SPSS, Chicago, IL, USA). Count data were expressed as a percentage.
2. A normality test and variance homogeneity test were conducted. Normally distributed
data with homogeneity were compared using one-way analysis of variance. Non-normally
distributed data were compared using Wilcoxon's two-sample rank sum test.
3. The incidence of adverse reactions between groups was compared using chi-square test. A
P value of < 0.05 was considered statistically significant. Results followed the
intention-to-treat principle.
Confidentiality:
Clinical trial observation forms and informed consents were password-protected. No person,
other than an authorized researcher, might be in contact with it.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05613257 -
Distal Targeter vs Free-hand
|
N/A | |
Completed |
NCT04340284 -
Adipose Tissue Derived Stromal Vascular Fraction (SVF) Application in Treatment of Long Bones Nonunion
|
Phase 1/Phase 2 | |
Recruiting |
NCT05699174 -
PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation
|
Phase 3 | |
Completed |
NCT05163795 -
Distal Femur Fracture Nonunion - Statistical Analysis Plan
|
||
Recruiting |
NCT03891888 -
Intramedullary Bone Grafting for Open Tibial Shaft Fractures
|
N/A | |
Recruiting |
NCT04299022 -
Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care
|
||
Recruiting |
NCT01958502 -
Evaluation the Treatment of Nonunion of Long Bone Fracture of Lower Extremities (Femur and Tibia) Using Mononuclear Stem Cells From the Iliac Wing Within a 3-D Tissue Engineered Scaffold
|
Phase 2 | |
Enrolling by invitation |
NCT03937310 -
NGS for Non-unions
|